"Tales From the Dark Stacks," an adult paranormal-themed book club will meet 1-2 p.m. Saturday, Feb. 14 at the Valencia ...

Inside a specially carved pocket in the stone, they placed a copper box filled with relics about the library and broader L.A.

These three homes each have a distinct vibe, but share a common thread: a comfortable, inviting spot to settle in when conditions call for staying put ...

In this city nestled in the San Gabriel foothills, seeing and being seen isn’t as much of an objective as gathering as a ...

Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its organization. The California pharma has stitched together a deal worth up to $840 ...

The company plans to integrate Dark Blue Therapeutics into its existing research organization to strengthen its early oncology discovery efforts. With annual revenue of nearly $36 billion and healthy ...

Amgen has acquired U.K.-based biotechnology company Dark Blue Therapeutics in a transaction valued at up to $840 million. Amgen on Tuesday said the deal adds an investigational small molecule that ...

This article first appeared on GuruFocus. Amgen (NASDAQ:AMGN) has agreed to acquire UK-based cancer drug developer Dark Blue Therapeutics in a deal valued at up to $840 million, as the company looks ...